# Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

> **NCT03565458** · PHASE1 · UNKNOWN · sponsor: **LG Chem** · enrollment: 48 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Gemigliptin
- **DRUG:** Dapagliflozin
- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT03565458
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-05
- **Primary completion:** 2018-08-20
- **Final completion:** 2018-12-22
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03565458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03565458, "Gemigliptin, Dapagliflozin, Empagliflozin DDI Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03565458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*